Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2023-01-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关于控股股东所持公司全部股份将被拍卖的第二次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the auction of all shares held by its controlling shareholder due to bankruptcy proceedings. It details the auction process, risks, legal considerations, and responsibilities for potential bidders. There are no financial statements, management discussions, or detailed financial data presented. The document serves as a notification and risk disclosure related to a capital event (auction of shares) rather than a financial report or earnings release. This fits the category of Capital/Financing Update (CAP), as it concerns changes in capital ownership and financing implications due to the auction of shares held by the controlling shareholder.
2023-01-10 Chinese
2022年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2022 annual performance forecast (业绩预告) from Harbin Yuheng Pharmaceutical Co., Ltd. It provides estimated net profit/loss figures for the full year 2022, explanations for the changes, and a risk warning. It explicitly states that the final financial data will be in the 2022 annual report. The document is short (1226 characters) and serves as a preliminary earnings forecast rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not the full Annual Report (10-K) or Interim Report (IR), nor is it a report publication announcement (RPA) because it contains substantive financial estimates and explanations. Therefore, the correct classification is Earnings Release (ER). FY 2022
2023-01-10 Chinese
关于对深圳证券交易所关注函回复说明的公告
Audit Report / Information Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. responding to a regulatory inquiry from the Shenzhen Stock Exchange regarding asset impairment testing. It includes extensive financial data, impairment testing methodologies, assumptions, and detailed calculations for intangible assets, inventory, fixed assets, goodwill, and development expenditures. The document references the 2022 fiscal year and includes audited and unaudited financial figures. It is not a full annual report but a comprehensive disclosure related to audit and accounting matters, specifically asset impairment and valuation. The presence of detailed impairment testing, accounting standards references, and audit confirmations aligns with the characteristics of an Audit Report / Information filing rather than an Annual Report or Earnings Release. The document is lengthy (15,000 characters) and contains substantive financial and accounting information, not merely an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2022
2023-01-03 Chinese
关于控股股东所持公司全部股份将被拍卖的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Harbin Yuheng Pharmaceutical Co., Ltd. regarding the judicial auction of all shares held by its controlling shareholder, Yuheng Group. It details the auction schedule, share quantities, and risks related to the potential change in control of the company. The document is relatively short (3160 characters) and serves as a notification of a significant corporate event (shareholder share auction) rather than a financial report or detailed analysis. It does not contain financial statements, earnings data, or management discussion. It is not a report publication announcement since it contains substantive information about the auction event itself. The content fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about a shareholder's shares being auctioned due to bankruptcy proceedings, which does not fit other more specific categories like Capital/Financing Update or Major Shareholding Notification because it is about judicial auction of shares held by a controlling shareholder, not a voluntary capital change or shareholding threshold crossing notification.
2022-12-28 Chinese
独立董事关于第六届董事会第三次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from the independent directors of Harbin Yuheng Pharmaceutical Co., Ltd. regarding their independent opinions on asset impairment provisions decided at the company's sixth board meeting. It references compliance with accounting standards and company bylaws, and confirms the appropriateness of the impairment decisions. The document is short (858 characters) and does not contain full financial statements or detailed financial analysis. It is an official announcement related to board meeting decisions but not a full management report or audit report. It is not a report publication announcement since it contains substantive independent director opinions. The content aligns best with Board/Management Information (MANG) as it relates to board meeting decisions and independent director opinions on financial matters.
2022-12-27 Chinese
关于对参股公司广州誉衡生物科技有限公司进行开发支出减值测试并予以减值的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the impairment testing and recognition of impairment losses on development expenditures of an associate company, Guangzhou Yuheng Biotechnology Co., Ltd. It details the impairment test rationale, the impact on net profit, and includes opinions from the board, audit committee, independent directors, and supervisors. The document is a formal announcement of a specific accounting event (impairment recognition) rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed audit opinions but rather a disclosure of impairment testing results and related board approvals. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about an accounting event and related board decisions, not a full Annual Report, Audit Report, or Interim Report.
2022-12-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.